Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['hero', 'enzamet', 'prostate', 'cart,(-cartitude)'] | 6/6/2022 8:59 | 1,530,000,000,000,000,000 | i think hall b1 suits well! saw here here at #asco19 giving the plenary discussion for s #enzamet study - now on the same main stage at #asco22 giving an excellent talk on #cart in #prostatecancer. my hero! | @cityofhope & @cityofhopeoc prof w focus on #kidneycancer, #prostatecancer, #bladdercancer & 90s rock. RTs not endorsements. COI: https://t.co/L7ihnCjLz5 | Individual | HCP |
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['enzamet', 'prostate', 'enzalu'] | 6/6/2022 7:52 | 1,530,000,000,000,000,000 | daily news #asco22 #enzamet - update confirms os benefit w enzalutamide in metastatic hormone-sensitive prostate cancer abstract: daily news: | #PsyOnc @CettroOncologia | Former Postdoc Fellow & Visiting Scholar @cityofhope | @IPOSPsychoOncol BOD 2021-2023 | #ASCO22 FCOI: https://t.co/wuOhYiJHBM | Individual | HCP |
Not Tagged | enzalutamide | Astellas,Pfizer | other | 1 | ['ovarian'] | 6/3/2022 7:32 | 1,530,000,000,000,000,000 | #asco2022 #specialcollection phase ii study of #enzalutamide in #androgen #receptor #positive recurrent, high- and low-grade #serous #ovariancancer | Gynecologic Oncology & Gynecologic Oncology Reports Official Jnls @SGO_org Editors-in-Chief @David_Cohn_MD @SusanModesitt #SocialMediaEditor @GreggNelsonERAS | Company / Organization | Publication / Journal |
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['enzamet', 'triplet', 'crpc', 'thanks'] | 6/6/2022 8:28 | 1,530,000,000,000,000,000 | thanks for highlights session #enzamet discussion. i agree it s not a strong case for the triplet, and would like to emphasise that. if outcomes with doublet are overall comparable, why take on extra toxicity, and why not keep one of the drugs for later mcrpc? #asco22 | Professor of medicine | medical oncologist | head EH clinical school | Chair, ANZUP | husband, father, grandfather, blessed | want to make a positive difference | Individual | HCP |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['arches'] | 6/4/2022 19:00 | 1,530,000,000,000,000,000 | it's always great speaking with , especially at #asco22. he stopped by to review the findings from the post-hoc analysis of the arches trial for #mhspc. | Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more. | Company / Organization | Publication / Journal |
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['pcsm', 'enzamet', 'prostate', 'triplet'] | 6/6/2022 8:39 | 1,530,000,000,000,000,000 | takeaways from #enzamet might be that, compared to best soc in a diverse population:
* weak adt alone not enough
* any of the doublets might be a good choice for #prostatecancer mhspc
* use of triplet might be best be left for highest risk (if pt able and willing)
#asco22 #pcsm | Professor of medicine | medical oncologist | head EH clinical school | Chair, ANZUP | husband, father, grandfather, blessed | want to make a positive difference | Individual | HCP |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['enzalu', 'arches'] | 6/6/2022 14:45 | 1,530,000,000,000,000,000 | clinical outcomes and safety of enzalutamide + adt in #mhspc in patients aged 75 and 75 years: #arches posthoc analysis. presentation by russell szmulewitz, md . #asco22 written coverage by > | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
Not Tagged | enzalutamide | Astellas,Pfizer | gu | 1 | ['great work', 'crpc'] | 6/6/2022 17:00 | 1,530,000,000,000,000,000 | great to see so much interest in tom westbrook s poster from the lab on transcriptional profiling of matched biopsies after enza in crpc at #asco22! great work tom! hope to get this out soon! | We study transcriptional regulation and epigenetics in lethal prostate cancer. Our goal is to develop new treatments to improve patient outcomes. | Individual | Research / Science |
Not Tagged | enzalutamide | astellas,pfizer | gu | 1 | ['pcsm', 'prostate', 'enzalu'] | 6/6/2022 9:37 | 1,530,000,000,000,000,000 | enzalutamide sustains survival benefit in mhspc with over 5 years follow-up #asco22 #urology #urologist #pcsm #prostatecancer | Expert clinical analysis. Practice advice. Policy perspectives. | Company / Organization | Publication / Journal |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['radio', 'prostate', 'arches', 'pfizer'] | 6/6/2022 10:00 | 1,530,000,000,000,000,000 | see a post hoc analysis of the arches study investigating association between psa progression & radiographic progression in pts w/ metastatic hormone-sensitive #prostatecancer receiving an androgen receptor inhibitor + adt or placebo + adt at #asco22 5072 | Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ | Company / Organization | Pharma / Biotech |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['prostate', '5074', 'arches', 'pfizer'] | 6/6/2022 11:00 | 1,530,000,000,000,000,000 | see a post hoc analysis of the arches study assessing prevalence of ddr alterations & associated baseline characteristics in pts w/ metastatic hormone-sensitive #prostatecancer receiving an androgen receptor inhibitor + adt or placebo + adt #asco22 5074 | Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ | Company / Organization | Pharma / Biotech |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['prostate', '5022', 'arches', 'pfizer'] | 6/6/2022 12:00 | 1,530,000,000,000,000,000 | an analysis of the arches study evaluating the association between the hsd3b1 genotype and outcomes in pts w/ metastatic hormone-sensitive #prostatecancer receiving an androgen receptor inhibitor + adt or placebo + adt is being presented at #asco22 5022 | Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ | Company / Organization | Pharma / Biotech |
Not Tagged | enzalutamide | astellas,pfizer | gu | 1 | ['prostate', 'enzalu'] | 6/6/2022 12:26 | 1,530,000,000,000,000,000 | having a sexual life under #enzalutamide remains a huge challenge ! #asco2022 #prostatecancer | Professor of Urology @HopPitieSalpe @APHP @Sorbonne_Univ_ Paris, France ???? @AFUrologie CCAFU chairman & @Uroweb ESOU chairman - Views my own | Individual | HCP |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['pcsm', 'prostate', 'arches'] | 6/6/2022 12:48 | 1,530,000,000,000,000,000 | dr. armstrong on recent arches data in metastatic hormone-sensitive prostate cancer #asco22 #urology #urologist #pcsm #prostatecancer | Expert clinical analysis. Practice advice. Policy perspectives. | Company / Organization | Publication / Journal |
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['pcsm', 'enzamet', 'prostate'] | 6/7/2022 11:02 | 1,530,000,000,000,000,000 | ian davis, mb, bs, phd, fracp, fachpm, from spoke about the enzamet trial for patients with metastatic hormone-sensitive prostate cancer. #asco22 #pcsm | | Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more. | Company / Organization | Publication / Journal |
arches | enzalutamide | astellas,pfizer | gu | 1 | ['radio', 'arches'] | 6/7/2022 10:30 | 1,530,000,000,000,000,000 | radiographic progression in the absence of psa progression in patients with #mhspc: posthoc analysis of #arches. presentation by . #asco22 written coverage by on urotoday > | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
enzamet | enzalutamide | astellas,pfizer | gu | 1 | ['pcsm', 'enzalu', 'enzamet', 'prostate'] | 6/7/2022 8:04 | 1,530,000,000,000,000,000 | #asco22 news: updated enzamet data presented by confirm the benefits of enzalutamide when added to best practice standard of care in metastatic hormone-sensitive #prostatecancer #pcsm | Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology. | Company / Organization | Media / News |
enzamet,arasens,peace1 | enzalutamide,abiraterone acetate,darolutamide,docetaxel | astellas,pfizer,bayer | gu | 1 | ['enzamet', 'prostate', 'triplet'] | 6/6/2022 8:32 | 1,530,000,000,000,000,000 | note #arasens and #peace1 were different designs and different populations to #enzamet, which had a much more diverse #prostatecancer population - maybe more generalisable? triplet good in those specific populations, and (maybe) in high volume synchronous m1 in enzamet. #asco22 | Professor of medicine | medical oncologist | head EH clinical school | Chair, ANZUP | husband, father, grandfather, blessed | want to make a positive difference | Individual | HCP |
ev-301 | enfortumab vedotin | astellas,seagen | gu | 1 | ['ev-301'] | 6/4/2022 17:35 | 1,530,000,000,000,000,000 | dr. matthew milowsky discusses the update results of ev-301 trial with 24mth mfu. very similar numbers as the nejm publication with a plateau pfs around 15-20%. #asco22 | Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer | Individual | HCP |
ev-301 | enfortumab,enfortumab vedotin | astellas,seagen | gu | 1 | ['ev-301', 'urothelial', 'enfortumab'] | 6/5/2022 10:23 | 1,530,000,000,000,000,000 | #asco22 news: updated ev-301 data show the survival advantage conferred by enfortumab vedotin over standard chemo is maintained over time in pretreated advanced urothelial cancer. read our report of the poster by et al | Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology. | Company / Organization | Media / News |
ev-301 | enfortumab,enfortumab vedotin | astellas,seagen | gu | 1 | ['ev-301', 'urothelial', 'enfortumab'] | 6/5/2022 8:30 | 1,530,000,000,000,000,000 | long-term outcomes in ev-301: 24-month findings from the phase 3 trial of enfortumab vedotin vs chemotherapy in patients with previously treated adv #urothelialcarcinoma. presented by . #asco22 written coverage > | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
EV-103 | enfortumab | astellas,seagen | gu | 1 | ['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gusm', 'bladder', 'enfortumab'] | 6/4/2022 13:06 | 1,530,000,000,000,000,000 | great to speak with ( ) on ev-103! cohort h! aiming to evaluating the activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive #bladdercancer who are cisplatin-ineligible #asco22 #gusm | The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only. | Company / Organization | Publication / Journal |
ev-301 | enfortumab,enfortumab vedotin | astellas,seagen | gu | 1 | ['urothelial carcinoma', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ev-301', 'enfortumab', 'urothelial', 'seagen'] | 6/4/2022 14:59 | 1,530,000,000,000,000,000 | 24-month findings from the phase 3 trial of enfortumab vedotin versus #chemotherapy in patients with previously treated advanced urothelial carcinoma. don't miss presenting long-term outcomes in ev-301 today at 4:30 pm in arie crown. #asco22 #gu | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
PACIFIC | durvalumab | astrazeneca | thoracic | 1 | ['durvalumab', 'nsclc', 'lung', 'radio', 'sclc'] | 6/5/2022 14:25 | 1,530,000,000,000,000,000 | outcomes with #durvalumab #icp after chemoradiotherapy in stage iiia-n2 non-small-cell lung cancer #nsclc #pacific trial #asco22 | The #OpenAccess journal of @myESMO dedicated to #oncology research | Company / Organization | Publication / Journal |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['pacific'] | 6/6/2022 12:06 | 1,530,000,000,000,000,000 | #asco22 pleased to present the egfr-mt subgrp analysis of pacific in which we see no diffs in pfs/os with durva v pbo, &no concerning safety signals you know you ve made it when comes to your poster | Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University | Individual | HCP |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['durvalumab', 'topaz-1'] | 6/4/2022 10:00 | 1,530,000,000,000,000,000 | in previously untreated advanced biliary tract #cancer, durvalumab plus gemcitabine and cisplatin demonstrated statistically significant prolonged overall survival versus placebo plus gemcitabine and cisplatin. more about the topaz-1 trial: #asco22 | NEJM Evidence, a new journal from NEJM Group, presents innovative #OriginalResearch and fresh, bold ideas in #ClinicalTrial design and clinical decision-making. | Company / Organization | Publication / Journal |
archon-1 | durvalumab | astrazeneca | thoracic | 1 | ['sclc', '8513', 'nsclc'] | 6/6/2022 12:20 | 1,530,000,000,000,000,000 | #asco22 dr. discusses abstracts #8511-8513 on immunotherapy in earlier stage nsclc. notes that we have made tremendous progress in curative-intent nsclc with recent advances changing soc. | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
himalaya | durvalumab,tremelimumab | astrazeneca,myriad genetics | Not Tagged | 1 | ['4074', 'improve '] | 6/5/2022 14:51 | 1,530,000,000,000,000,000 | every day, myriad genetics works to improve the health and well-being of patients through genetic insights. if you re in chicago, visit booth 4074 and see how you can find treatment clarity from cancer complexity. #asco22 | Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. | Company / Organization | Pharma / Biotech |
Not Tagged | osimertinib | astrazeneca | Not Tagged | 1 | ['osimertinib'] | 6/6/2022 8:06 | 1,530,000,000,000,000,000 | goldman et al poster on met adc+osimertinib in patients with osimertinib resistance and met expression. orr 58%. #asco22 | Medical Oncologist at Memorial Sloan Kettering. Clinical focus on patients with lung & thymic cancers. COI: https://t.co/lXxGGb6HFw | Individual | HCP |
PrE0505 | durvalumab | astrazeneca | thoracic | 1 | ['durvalumab', 'mesothelioma'] | 6/6/2022 9:01 | 1,530,000,000,000,000,000 | at the #asco22 clinical controversies session on #mesothelioma? read about the phase ii trial on durvalumab plus platinum-pemetrexed for unresectable mesothelioma led by speaker | Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians. | Company / Organization | Publication / Journal |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['durvalumab', 'topaz-1', '4075'] | 6/4/2022 12:25 | 1,530,000,000,000,000,000 | details of topaz-1 by in #asco22 with insight on the impact of region and viral hepatitis in #biliarytracttumors treated with #durvalumab and cisgem. p4075. trend towards benefit regardless of region and hepatitis status remember, not powered for subgroup analyses | Consultant in Medical Oncology with expertise in HPB and Neuroendocrine Tumours. Fundación Jiménez Díaz University Hospital. #BiliaryTractTumor #NET | Individual | HCP |
Not Tagged | acalabrutinib | astrazeneca | lymphoma,myeloid | 1 | ['acalabrutinib', 'cll', 'leusm'] | 6/4/2022 14:57 | 1,530,000,000,000,000,000 | long-term follow-up supports acalabrutinib-based regimens in treatment-na ve cll #asco22 #leusm #oncology | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['astrazeneca'] | 6/6/2022 8:20 | 1,530,000,000,000,000,000 | we are pushing the boundaries of science in immuno-oncology. this includes unlocking the full potential of bispecific antibodies to develop more targeted and powerful options for patients. learn more about our advances in io. #asco22 | We're driven by innovative science to deliver life-changing medicines to millions of people worldwide. Community Guidelines: https://t.co/Hj5OdRQOYy | Company / Organization | Pharma / Biotech |
not tagged | durvalumab | astrazeneca | other | 1 | ['bcsm', 'durvalumab', 'tnbc'] | 6/6/2022 12:11 | 1,530,000,000,000,000,000 | . will present "clinical outcomes and immune markers by race in a phase i/ii clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage #tnbc" at 1:15pmcdt #asco22 in hall b. #bcsm | Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer. | Company / Organization | Hospital / Clinic |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lcsm,(-blcsm)', 'lung', 'osimertinib'] | 6/6/2022 13:33 | 1,530,000,000,000,000,000 | presented at #asco22 -- helpful chart to compare current results from some of the clinical trial options available to post-osimertinib progression. #asco22 #lcsm #egfr #lungcancer | Co-Founder, @EGFRResisters LC Patient Group; writer for https://t.co/W6HLnN0ibZ; lc advocate/survivor; dx stage IV 2013
https://t.co/2UwibVmlPs | Individual | Advocacy / Charity |
Not Tagged | osimertinib | astrazeneca | other | 1 | ['osimertinib', 'biomarker'] | 6/6/2022 13:36 | 1,530,000,000,000,000,000 | #asco22 dr. outlines some different strategies for overcoming osimertinib resistance. this will be guided by biomarkers and will prompt the question of earlier combination strategies to prevent resistance. | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['topaz-1', 'in person'] | 6/4/2022 12:43 | 1,530,000,000,000,000,000 | ruth he, md, phd ( ) a coinvestigator on a subgroup analysis of the topaz-1 study, enjoying #asco22 in person! | Fighting a Smarter War on Cancer at the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. | Company / Organization | Hospital / Clinic |
OPERA,PANDORA,DANISH | durvalumab | astrazeneca | gi | 1 | ['improve ', 'rectal'] | 6/4/2022 15:45 | 1,530,000,000,000,000,000 | rectal cancer #asco22 poster discussions: 1) contact brachy may improve organ preservation in ct2-t3 (opera) w/crt but more bleeding, 2) phii pandora long-course crt + durva x3 32.7% #pcr, 3) phii danish ii long-course crt to tumors <6 cm from verge 86% ccr followed on nom | Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope | Individual | HCP |
not tagged | durvalumab | astrazeneca | other | 1 | ['amazing work', 'durvalumab', 'tnbc', 'breast'] | 6/6/2022 11:20 | 1,530,000,000,000,000,000 | amazing work on outcomes and race in early-stage tnbc receiving durvalumab! #asco22 #breastcancer #equity | Heme/Onc #Oncology fellow at @YaleHemOnc @YaleCancer. Interested in #Melanoma #MELSM #LungCancer #LCSM #ClinicalTrials #TranslationalMedicine. ?????????? | Individual | HCP |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['sclc', 'durvalumab', 'radio', 'nsclc', 'pacific'] | 6/6/2022 14:47 | 1,530,000,000,000,000,000 | durvalumab (durva) after chemoradiotherapy (crt) in unresectable, stage iii, egfr mutation-positive (egfrm) nsclc: a post hoc subgroup analysis from pacific. #asco22 repeat after me: immunotherapy in patients with egfrm stage iii nsclc is unclear | Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['astrazeneca'] | 6/3/2022 8:00 | 1,530,000,000,000,000,000 | at #asco22, our teams are presenting new data in oncology, participating in scientific exchange and some are catching their first american baseball game! | We're driven by innovative science to deliver life-changing medicines to millions of people worldwide. Community Guidelines: https://t.co/Hj5OdRQOYy | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['lung', 'detection', 'astrazeneca'] | 6/4/2022 11:21 | 1,530,000,000,000,000,000 | will be at #asco22 at the astrazeneca booth on 6th & 7th june. do drop in learn more about s partnership with astrazeneca & how we are working together to achieve earlier detection of #lungcancer. #oncology | Our mission is to make healthcare more affordable and accessible through the power of deep learning | Company / Organization | Healthcare |
inspire | durvalumab | astrazeneca | gu | 1 | ['inspire'] | 6/5/2022 9:22 | 1,530,000,000,000,000,000 | watch stephen gruber, m.d., ph.d., m.p.h., share details on the inspire study and provide insights on how city of hope is blazing a trail in precision medicine. #asco22 | City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases. | Company / Organization | Hospital / Clinic |
sakk 06/17 | durvalumab | astrazeneca | gu | 1 | ['durvalumab', 'urothelial', 'sakk 06/17'] | 6/5/2022 10:00 | 1,530,000,000,000,000,000 | perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive #urothelialcarcinoma: primary analysis of the single-arm phase ii trial sakk 06/17. presented by richard cathomas, md. #asco22 written coverage by > | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
Not Tagged | Not Tagged | astrazeneca | other | 1 | ['biomarker', 'ovarian', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 12:08 | 1,530,000,000,000,000,000 | precision medicine is transforming the way advanced #ovariancancer is treated. comprehensive biomarker testing can help patients make informed decisions about their treatment. at #asco22, learn more about getting the right treatment to the right patients at the right time. | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['thank you', 'astrazenecaus', 'astrazeneca'] | 6/5/2022 13:01 | 1,530,000,000,000,000,000 | thank you for talking #patientempowerment with us at #asco22 | Empowers patients & care partners at every step of their cancer journey. Empowered #patientchat host.
Get personalized support!
Text ‘EMPOWER’ to 833-213- 665 | Company / Organization | Advocacy / Charity |
not tagged | not tagged | astrazeneca | other | 1 | ['breast', 'astrazeneca'] | 6/6/2022 7:35 | 1,530,000,000,000,000,000 | at , we are breaking swim lanes to bring about a new era of breast cancer research with the aim of improving patient outcomes. read about our approach in this new blog from and i. #asco22 | Trained as a Clinical Oncologist and PhD. Now a cancer drug developer. Mum to two budding scientists. Love skiing, dogs and piano! | Individual | Pharma / Biotech |
Not Tagged | Not Tagged | astrazeneca | thoracic | 1 | ['lung', 'thoracic', 'astrazeneca'] | 6/6/2022 10:44 | 1,530,000,000,000,000,000 | at asco22 gto visit with my favorite thoracic oncologist, superstar . a former fellow & faculty now with leading lung effort. | Oncologist, educator, researcher, cancer survivor x 2, co-host ASCO Oncology, Etc. podcast, history buff, husband, Dad - but not in that order! | Individual | HCP |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['topaz-1', 'durvalumab'] | 6/3/2022 7:08 | 1,530,000,000,000,000,000 | well, this publication is extremely timely results from topaz-1, presented initially at #gi22, now in for #asco22 day 1. durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer | nejm evidence | Physician-Scientist/Clinical Cancer Biologist. Clinical focus: GI Oncology/Neuro-Oncology. In lab: #TunnelingNanotubes #Exosomes and drivers of Chemoresistance | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['astrazenecaus', 'astrazeneca'] | 6/3/2022 8:22 | 1,530,000,000,000,000,000 | a reminder to mark your calendars for chatrick paul s upcoming fireside chat with on astrazeneca s highlights from #asco22. register here: | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
Not Tagged | acalabrutinib | astrazeneca | lymphoma | 1 | ['acalabrutinib', 'marginal zone lymphoma', 'lymphoma'] | 6/4/2022 7:00 | 1,530,000,000,000,000,000 | results from a clinical trial of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma will be presented today at 8 a.m. cst. #asco22 | City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases. | Company / Organization | Hospital / Clinic |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['durvalumab', '#gi', 'topaz-1'] | 6/4/2022 12:34 | 1,530,000,000,000,000,000 | we suspected as much at #gi22 but topaz-1 (durvalumab + gem/cis) really does appear to be establishing the new 1st line standard of care in biliary tract cancer #asco22 | Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own. | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['astrazenecaus', 'astrazeneca'] | 6/4/2022 14:21 | 1,530,000,000,000,000,000 | #yourcancer is at #asco22 spotlighting the individuals and organizations on the frontlines of cancer care. visit our booth to hear their stories and learn more about the work to redefine cancer care for all: | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
himalaya | durvalumab,tremelimumab | astrazeneca,myriad genetics | gi | 1 | ['4074'] | 6/4/2022 15:14 | 1,530,000,000,000,000,000 | if you're attending #asco22, stop by booth 4074 and learn how precise oncology solutions from myriad genetics helps providers with determining effective and personalized treatment plans for patients with cancer. #oncology #genetictesting | Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. | Company / Organization | Pharma / Biotech |
Not Tagged | adavosertib | astrazeneca | other | 1 | ['gyn', 'adavosertib', 'ovarian'] | 6/4/2022 17:03 | 1,530,000,000,000,000,000 | adavosertib (wee1 inhibitor) is a hot topic today - taking advantage of the dependence of p53 mutated #ovariancancer on the g2/m checkpoint this agent was active as a single agent in ccne1 amplifed tumors and in combination with carboplatin in all comers! #gyncsm #asco22 | Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. #JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['$azn'] | 6/5/2022 7:15 | 1,530,000,000,000,000,000 | another big asco for $azn. | Writing and events at STAT. This is biology's century; Every data point has a face. Part of team that won ‘21 Polk Award. | Individual | Research / Science |
dramatic | Not Tagged | astrazeneca | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 10:06 | 1,530,000,000,000,000,000 | dramatic study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer #breastcancer #her2 | ??Diagnostics, ?? Analysis, ?? Laboratory | Individual | Research / Science |
Not Tagged | Not Tagged | astrazeneca | other | 1 | ['biomarker', 'ovarian', 'astrazeneca'] | 6/5/2022 15:21 | 1,530,000,000,000,000,000 | biomarkers may identify ovarian cancer patients who benefit from astrazeneca wee1 inhibitor. researchers at asco shared data pointing to gene amplification, protein overexpression, and tp53 mutations as biomarkers for identifying best responders to... | null | Bot / Aggregator | Media / News |
Not Tagged | adavosertib | astrazeneca | other | 1 | ['ovarian', 'adavosertib', 'biomarker', 'astrazeneca'] | 6/6/2022 0:53 | 1,530,000,000,000,000,000 | adavorsertib, astrazeneca's wee1 inhibitor, may potentially benefit biomarker selected advanced ovarian cancer patients, as per the data presented in asco 2022. #astrazeneca #wee1 #asco #adavosertib #cancer #ovariancancer #health | PharmaScroll is a diligent business consulting and market research firm focused solely towards chronic disease indications. | Company / Organization | Consulting / Analytics |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lung', 'tagrisso', 'osimertinib'] | 6/6/2022 8:52 | 1,530,000,000,000,000,000 | how many times do we value patients' preferences when choosing an oncology drug? in this pt based survey we asked this question to pts taking osimertinib for adjuvant lung cancer. come an check it out poster 147 #asco22 #lungcancer #tagrisso #patientpreferences #roswellpark | Hematology-Oncology MD
Roswell Park HemOnc Fellow | Individual | HCP |
Not Tagged | osimertinib | astrazeneca | Not Tagged | 1 | ['osimertinib'] | 6/6/2022 9:10 | 1,530,000,000,000,000,000 | poster at #asco22 on mechanisms of resistance to osimertinib. squamous/neurowndocrine transformation in a significant number. 3.2% c797s, 10% met. only able to do because of #mskimpact | Medical Oncologist at Memorial Sloan Kettering. Clinical focus on patients with lung & thymic cancers. COI: https://t.co/lXxGGb6HFw | Individual | HCP |
not tagged | not tagged | astrazeneca | other | 1 | ['breast', 'biomarker', 'astrazeneca', 'astrazenecaus'] | 6/6/2022 10:37 | 1,530,000,000,000,000,000 | #her2 is a growth-promoting protein expressed on the surface of certain tumors and is one of many biomarkers expressed in #breastcancer. data presented at #asco22 may have the potential to transform how breast cancer is classified and treated. | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['in person', 'lcsm,(-blcsm)', 'osimertinib'] | 6/6/2022 10:47 | 1,530,000,000,000,000,000 | happy to finally meet in person and more importantly to have contributed to this work on efficacy of osimertinib in uncommon egfr . great initiative led by and . #asco22 #lcsm | MD MSc, Thoracic Oncology & Respiratory Medicine, master in hospital and health care management Hasselt - Belgium - PhD candidate LUMC Leiden - he/him | Individual | HCP |
not tagged | acalabrutinib | astrazeneca | lymphoma | 1 | ['calquence', 'cll'] | 6/6/2022 11:02 | 1,530,000,000,000,000,000 | calquence-containing treatment regimens produce more favorable results in both progression-free survival and overall response rate at five years, for patients with cll, #asco22 research presented by dr. sharman from showed. | Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey. | Company / Organization | Advocacy / Charity |
unicorn | osimertinib | astrazeneca | thoracic | 1 | ['in person', 'lcsm,(-blcsm)', 'osimertinib'] | 6/6/2022 11:35 | 1,530,000,000,000,000,000 | humbled to finally meet in person prof jair bar. presenting in the poster session the unicorn study: uncommon egfr mutations on osimertinib, real-life data with results, on brain efficacy and resistance mechanisms. #asco22 #lcsm | Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm | Individual | HCP |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['durvalumab', 'topaz-1'] | 6/6/2022 12:00 | 1,530,000,000,000,000,000 | original article: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (topaz-1), by oh et al. a phase 3 study, topaz-1, evaluated immunotherapy plus chemotherapy as first-line treatment for advanced biliary tract cancer. #asco22 | NEJM Evidence, a new journal from NEJM Group, presents innovative #OriginalResearch and fresh, bold ideas in #ClinicalTrial design and clinical decision-making. | Company / Organization | Publication / Journal |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lcsm,(-blcsm)', 'osimertinib'] | 6/6/2022 12:23 | 1,530,000,000,000,000,000 | #asco22 abs 8520 what makes it worth it to patients? survey of pt preferences when deciding on adj osimertinib benefit. employment status & educational level assoc w osi uptake if it provides 1 yr+ dfs advantage by #lcsm | Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her) | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['$azn'] | 6/6/2022 13:45 | 1,530,000,000,000,000,000 | the day after major positive clinical presentation, concurrent publication, and standing ovation for study at plenary session, $azn sheds 3.5% / $7b in market cap. seems like wall st 'knew it already' and wasn't impressed. | Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI. | Individual | HCP |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lcsm,(-blcsm)', 'lung', 'osimertinib'] | 6/6/2022 13:48 | 1,530,000,000,000,000,000 | excited to participate in this academic study providing evidence on the use of osimertinib in uncommon egfr mutations in patients with lung cancer. #asco22 #lcsm | Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm | Individual | HCP |
Not Tagged | durvalumab | astrazeneca | thoracic | 1 | ['durvalumab', 'lung'] | 6/6/2022 14:06 | 1,530,000,000,000,000,000 | mandy moore, pharmd, phd candidate at the is presenting our research on durvalumab for patients with stage iii unresectable non-small cell lung cancer in chicago, il today. way to go mandy! | UT Austin & UT Health San Antonio Professor of Pharmacy & Medicine, Director of Translational Science PhD and TL1 Programs, Proud Father of Alexa & Andrew Frei | Individual | Research / Science |
himalaya,topaz-1 | tremelimumab,durvalumab | astrazeneca | gi | 1 | ['himalaya', 'topaz1'] | 6/6/2022 15:13 | 1,530,000,000,000,000,000 | its being a very exiting week for hepato-biliary! first #topaz1 and now #himalaya! and all while #asco22 is still ongoing. | Consultant in Medical Oncology with expertise in HPB and Neuroendocrine Tumours. Fundación Jiménez Díaz University Hospital. #BiliaryTractTumor #NET | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['astrazeneca'] | 6/6/2022 16:07 | 1,530,000,000,000,000,000 | . partners with nhs for large-scale cancer study
(free w/ registration) #oncology | Med-tech's trusted news source. Lynn Yoffee, Holland Johnson, Mark McCarty, Annette Boyle, Catherine Longworth, Andrea Applegate | Company / Organization | Media / News |
Not Tagged | trastuzumab | astrazeneca | Not Tagged | 1 | ['enhertu', '$azn'] | 6/3/2022 13:45 | 1,520,000,000,000,000,000 | key thing to look for on sunday is enhertu efficacy in ihc2+ vs ich1+. i'm hoping $dknsy $azn provide that! #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | osimertinib | astrazeneca | Not Tagged | 1 | ['osimertinib'] | 6/3/2022 15:09 | 1,530,000,000,000,000,000 | #asco22 not all patients received osimertinib as most recent therapy (any retreatment effect?) and 30 pts had untreated brain metastases (prior to amendment). overall, heavily pretreated, real world population. | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | lymphoma,myeloid | 1 | ['cll', 'leukemia', 'astrazenecaus', 'astrazeneca'] | 6/4/2022 9:04 | 1,530,000,000,000,000,000 | this #asco22, we re sharing results from two phase iii trials in adults with chronic lymphocytic #leukemia. learn about what these results could mean for patients with #cll: | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['topaz-1'] | 6/4/2022 12:42 | 1,530,000,000,000,000,000 | update on topaz-1 durva in btc in combination of with ctx. does region matter? make up your own mind.
#asco, #btc #liver cancer | Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine | Individual | HCP |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['topaz-1'] | 6/4/2022 14:05 | 1,530,000,000,000,000,000 | update of topaz-1 ; ctx plus durva in btc --> no impact of underlying hbv on survival or efficacy of durva.
#btc #livercancer | Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine | Individual | HCP |
caspian | durvalumab | astrazeneca | thoracic | 1 | ['caspian', 'biotec'] | 6/4/2022 16:29 | 1,530,000,000,000,000,000 | we will discuss astum005, the first pd1 mab/chemo combo international randomized ph3 trial that hit os hr of 0.63, compared the current soc impowe133 s 0.70 and caspian of 0.73. #indatawetrust #asco2022 | A biotech junky and biz executive with permanent head damage (a.k.a Ph.D.). Tweets and opinions are my own. #InScienceWeTrust, #InDataWeTrust | Individual | Research / Science |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['thanks'] | 6/4/2022 23:32 | 1,530,000,000,000,000,000 | thanks for showcasing the egfr subgroup analysis of pacific- catch it at the poster session on monday 6/6 8-11am | Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 9:32 | 1,530,000,000,000,000,000 | dramatic study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer by | We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: https://t.co/F2W5HeStyV | Company / Organization | Media / News |
Not Tagged | Not Tagged | astrazeneca | other | 1 | ['breast', 'astrazeneca'] | 6/5/2022 9:39 | 1,530,000,000,000,000,000 | 'dramatic' study results for astrazeneca, daiichi drug suggest new way to treat aggressive breast cancer via | former Cytotechnologist,previously worked at a garden center, #ClimateCrisis,#BLM,#NativeAmericans,I stand w/#Ukraine.
MyDadservedintheUSArmy#Korea???????? | Individual | Research / Science |
Not Tagged | medi-5752 | astrazeneca | Not Tagged | 1 | ['medi5752 '] | 6/5/2022 10:32 | 1,530,000,000,000,000,000 | gives an update on the first-in-human study of medi5752 at the #asco22 bispecifics clinical science symposium - read more on medi5752 in : | Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Tweets are my own. She/her | Individual | Publication / Journal |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['astrazeneca'] | 6/5/2022 11:37 | 1,530,000,000,000,000,000 | well done paul! | Husband, Dad | Urological Surgeon | Director Edinburgh Bladder Cancer Surgery @EdinBC_surgery | EAU NMIBC Guidelines panel | Golfer. Views my own | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['thanks', 'astrazeneca'] | 6/5/2022 14:06 | 1,530,000,000,000,000,000 | thanks param | ?? Radiation Oncologist and more...
?? Bergonie, Bordeaux, France
GU and Sarcoma Team
?? CC-AFU
?? GETUG, AFU, GFRU and GSF-GETO | Individual | HCP |
Not Tagged | durvalumab | astrazeneca | gu | 1 | ['durvalumab', 'bladder'] | 6/5/2022 15:03 | 1,530,000,000,000,000,000 | #cctg @ #asco22 #asco2022 cctg bl.13
a randomized phase ii trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (nct03768570)
abstract link: | The Canadian Cancer Trials Group is a cancer clinical trials research cooperative that runs phase I-III trials to test anti-cancer and supportive therapies. | Company / Organization | Healthcare |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['astrazeneca'] | 6/5/2022 18:58 | 1,530,000,000,000,000,000 | it was great to talk to navigates an international path from clinical educator in oncology to global leadership in oncology. the importance of putting your team first!! - #asco22 | Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['$azn'] | 6/6/2022 6:05 | 1,530,000,000,000,000,000 | starting a position in $azn given asco data. lt perspective. will accumulate, but no rush. | ????citizen; ???? born and raised; ????living - Bern; Stock/options trading; I like bios; data analytics / visualization - opinions just mine | Individual | Finance / Investment |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['congrat', '$azn'] | 6/6/2022 6:44 | 1,530,000,000,000,000,000 | $azn congrats on winning asco, your prize is -1.2% | Biotech Investor/Trader. Chartist, w some humor mixed in. Have been working in the biotech industry for 20+years. Please do your own DD on any play I mention. | Individual | Finance / Investment |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['astrazeneca', '$azn'] | 6/6/2022 7:29 | 1,530,000,000,000,000,000 | $azn this new, astrazeneca drug will replace chemotherapy and cut death rates in half. | This week I will mostly be pointing out political deflection by the Conservative party. | Individual | Blogger / Random / Other |
not tagged | not tagged | astrazeneca | other | 1 | ['beat', 'breast', 'astrazeneca', '$azn'] | 6/6/2022 8:39 | 1,530,000,000,000,000,000 | $azn new article : astrazeneca's breast cancer drug beats expectations, and other asco highlights get all the latest $azn related news here : | We'll make staying up-to-date on financials news easy for you. Discover how https://t.co/qYtx6dQ3dV revolutionizes how you gather financial related news | Bot / Aggregator | Finance / Investment |
Not Tagged | durvalumab | astrazeneca | other | 1 | ['durvalumab', 'meet you', 'tnbc', 'breast'] | 6/6/2022 8:46 | 1,530,000,000,000,000,000 | it was a pleasure to meet you @#asco22 i enjoyed the discussion of your neoadjuvant durvalumab trial. #earlystagetnbc #endbbreastcancer | Co-Operations Mgr. RVA Career ExpoSpring 2018 #ProjectManagement #Consulting #VendorManagement #TrainingandDevelopment | Individual | Blogger / Random / Other |
not tagged | not tagged | astrazeneca | other | 1 | ['beat', 'breast', 'astrazeneca', '$azn'] | 6/6/2022 8:54 | 1,530,000,000,000,000,000 | $azn astrazeneca's breast cancer drug beats expectations, and other asco highlights | GetOnTrade is a news platform to help you stay up-to-date with the latest stock market news. We are not financial advisor(please do your own due diligence). | Bot / Aggregator | Finance / Investment |
not tagged | osimertinib | astrazeneca | not tagged | 1 | ['congrat', 'osimertinib'] | 6/6/2022 9:46 | 1,530,000,000,000,000,000 | congratulations on excellent international collaboration on osimertinib in egfr uncommon mutations and poster presentation #asco2022 | Thoracic medical oncologist @Davidoff Cancer Centre, wife, mother and professional dog walker | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['$azn'] | 6/6/2022 10:37 | 1,530,000,000,000,000,000 | fat lot of good that standing ovation did then $azn #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lung', 'osimertinib'] | 6/6/2022 11:02 | 1,530,000,000,000,000,000 | also in non-small cell #lungcancer: dr. angel mier-hicks with his poster on preferences for adjuvant osimertinib after complete surgical resection #asco22 | Roswell Park brings together the best medical & scientific minds in cancer care. We are the only NCI-designated comprehensive cancer center in Upstate New York. | Company / Organization | Hospital / Clinic |
not tagged | not tagged | astrazeneca | other | 1 | ['beat', 'breast', 'astrazeneca', '$azn'] | 6/6/2022 11:10 | 1,530,000,000,000,000,000 | $azn key news update
astrazeneca's breast cancer drug beats expectations stock alerts, news, and trade ideas at #daytrading #stocks #stockmarket | Profit faster with live SMS halt alerts. Join today and also gain access to volatility tools, buy/sell sentiment, historic market data, and more. | Company / Organization | Finance / Investment |
not tagged | not tagged | astrazeneca | other | 1 | ['beat', 'breast', 'astrazeneca'] | 6/6/2022 11:23 | 1,530,000,000,000,000,000 | astrazeneca s breast cancer drug beats expectations, and other asco highlights via | Get the Latest Social Media Buzz from #ASCO22!!! | Company / Organization | Media / News |
not tagged | durvalumab | astrazeneca | thoracic | 1 | ['sclc', 'durvalumab', 'nsclc'] | 6/6/2022 12:20 | 1,530,000,000,000,000,000 | #asco22 dr. also discussed phase i study of radiation with durvalumab in nsclc by dr. . safety reassuring but some feasibility challenges. when is it appropriate or better to omit chemotherapy? | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['sclc', 'lcsm,(-blcsm)', 'nsclc', 'pacific', 'aura '] | 6/6/2022 16:38 | 1,530,000,000,000,000,000 | important poster from regarding egfr nsclc. i ve always felt unsure about durva for these patients; good to see post-hoc pacific data (n=35) showing no pfs or os differences between io vs observation. await laura rct results. #asco22 #lcsm | Thoracic oncologist @ CU | Interested in targeted therapies and novel biomarkers | Dabble with piano, film, and skiing on the side | Alum @Penn & @KeckMedUSC | Individual | HCP |
Not Tagged | Not Tagged | astrazeneca | Not Tagged | 1 | ['in person', 'so great', 'astrazeneca'] | 6/6/2022 16:41 | 1,530,000,000,000,000,000 | so great to be back in person at asco and catch up with my mentor and friend in person. | null | Individual | HCP |